摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-�f-1-氮杂螺[3.5]壬烷 | 1214875-46-3

中文名称
6-�f-1-氮杂螺[3.5]壬烷
中文别名
6-氧杂-1-氮杂-螺[3.5]壬烷;6-噁-1-氮杂螺[3.5]壬烷
英文名称
6-Oxa-1-azaspiro[3.5]nonane
英文别名
8-oxa-1-azaspiro[3.5]nonane
6-�f-1-氮杂螺[3.5]壬烷化学式
CAS
1214875-46-3
化学式
C7H13NO
mdl
——
分子量
127.18
InChiKey
YLIPWBZIBAGXLT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    207.8±13.0 °C(Predicted)
  • 密度:
    1.04±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934999090

文献信息

  • HETEROCYCLIC COMPOUND
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US20210087186A1
    公开(公告)日:2021-03-25
    The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.
    本发明提供一种具有降低葡糖鞘脂的作用(例如促进葡糖鞘脂代谢、抑制葡糖鞘脂合成、促进葡糖鞘脂分解等)的化合物,预计可用作预防或治疗溶酶体疾病(例如高雪氏病)、神经退行性疾病(例如帕森病、路易体痴呆症、多系统萎缩症)等的药剂。本发明涉及一种由式(I)表示的化合物 其中每个符号如说明书中所述,或其盐。
  • SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US20200385345A1
    公开(公告)日:2020-12-10
    The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    本发明提供一种具有促进促觉素2型受体激动剂活性的取代吡咯烷化合物。一种由式(I)表示的化合物:其中每个符号如规范中所述,或其盐,具有促觉素2型受体激动剂活性,并可用作预防或治疗嗜睡症的药物。
  • TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE
    申请人:Daiichi Sankyo Company, Limited
    公开号:EP1942109A1
    公开(公告)日:2008-07-09
    A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or an alkoxy group, R3 represents hydrogen atom, a halogen atom, hydroxyl group, or an alkoxy group, R4 represents hydrogen atom, or an alkyl group, Z1 and Z2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, Z3 represents cyano group, an alkyl group, an alkenyl group and the like, Z4 represents an alkyl group, an alkenyl group, an alkynyl group and the like, and ---- represents a single bond or a double bond], which shows high antitumor effect against cancer cells including drug resistant cells.
    一个由通式(1)表示的化合物,其中[X1和X2代表氢原子,卤素原子,羟基等,R1代表苯基,R2代表烷基,烯基或烷氧基,R3代表氢原子,卤素原子,羟基或烷氧基,R4代表氢原子或烷基,Z1和Z2代表氢原子,卤素原子,羟基等,Z3代表基,烷基,烯基等,Z4代表烷基,烯基,炔基等,----代表单键或双键],对包括药物耐药细胞在内的癌细胞表现出高抗肿瘤效果。
  • [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
    申请人:HARVARD COLLEGE
    公开号:WO2015103583A1
    公开(公告)日:2015-07-09
    Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.
    本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II'),以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
  • Taxane Compound Having Azetidine Ring Structure
    申请人:Uoto Kouichi
    公开号:US20090186868A1
    公开(公告)日:2009-07-23
    A compound represented by the general formula (1) [X 1 and X 2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R 1 represents a phenyl group, R 2 represents an alkyl group, an alkenyl group, or an alkoxy group, R 3 represents hydrogen atom, a halogen atom, hydroxyl group, or an alkoxy group, R 4 represents hydrogen atom, or an alkyl group, Z 1 and Z 2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, Z 3 represents cyano group, an alkyl group, an alkenyl group and the like, Z 4 represents an alkyl group, an alkenyl group, an alkynyl group and the like, and represents a single bond or a double bond], which shows high antitumor effect against cancer cells including drug resistant cells.
    一种化合物由通式(1)表示 [其中X1和X2代表氢原子、卤素原子、羟基等,R1代表苯基,R2代表烷基、烯基或烷氧基,R3代表氢原子、卤素原子、羟基或烷氧基,R4代表氢原子或烷基,Z1和Z2代表氢原子、卤素原子、羟基等,Z3代表基、烷基、烯基等,Z4代表烷基、烯基、炔基等,且表示单键或双键],对包括耐药细胞在内的癌细胞具有高抗肿瘤效果。
查看更多

同类化合物

(3S,4R)-3-氟四氢-2H-吡喃-4-胺 鲁比前列素中间体 顺式-3-溴<2-(2)H>四氢吡喃 顺-4-氨基四氢吡喃-3-醇 顺-4-(四氢吡喃-2-氧)-2-丁烯-1-醇 顺-3-Boc-氨基-四氢吡喃-4-羧酸 锡烷,三丁基[3-[(四氢-2H-吡喃-2-基)氧代]-1-炔丙基]- 螺[金刚烷-2,2'-四氢吡喃]-4'-醇 蒿甲醚四氢呋喃乙酸酯 蒜味伞醇B 蒜味伞醇A 茉莉吡喃 苯基2,4-二氯-5-氨磺酰苯磺酸酯 苄基2,3-二-O-乙酰基-4-脱氧-4-C-硝基亚甲基-β-D-阿拉伯吡喃果糖苷 膜质菊内酯 红没药醇氧化物A 红没药醇氧化物 科立内酯 硅烷,(1,1-二甲基乙基)二甲基[[4-[(四氢-2H-吡喃-2-基)氧代]-5-壬炔基]氧代]- 甲磺酸酯-四聚乙二醇-四氢吡喃醚 甲基[(噁烷-3-基)甲基]胺 甲基6-氧杂双环[3.1.0]己烷-2-羧酸酯 甲基4-脱氧吡喃己糖苷 甲基3-脱氧-3-硝基-beta-L-核吡喃糖苷 甲基2,4,6-三脱氧-2,4-二-C-甲基吡喃葡己糖苷 甲基1,2-环戊烯环氧物 甲基-[2-吡咯烷-1-基-1-(四氢-吡喃-4-基)-乙基]-胺 甲基-(四氢吡喃-4-甲基)胺 甲基-(四氢吡喃-2-甲基)胺盐酸盐 甲基-(四氢吡喃-2-甲基)胺 甲基-(四氢-吡喃-3-基-胺 甲基-(四氢-吡喃-3-基)-胺盐酸盐 甲基-(4-吡咯烷-1-甲基四氢吡喃-4-基)-胺 甲基(5R)-3,4-二脱氧-4-氟-5-甲基-alpha-D-赤式-吡喃戊糖苷 环氧乙烷-2-醇乙酸酯 环己酮,6-[(丁基硫代)亚甲基]-2,2-二甲基-3-[(四氢-2H-吡喃-2-基)氧代]-,(3S)- 环丙基-(四氢-吡喃-4-基)-胺 玫瑰醚 独一味素B 溴-六聚乙二醇-四氢吡喃醚 氯菊素 氯丹环氧化物 氨甲酸,[[(四氢-2H-吡喃-2-基)氧代]甲基]-,乙基酯 氨甲酸,[(4-氨基四氢-2H-吡喃-4-基)甲基]-,1,1-二甲基乙基酯(9CI) 氧杂-3-碳酰肼 氧化氯丹 正-(四氢-4-苯基-2h-吡喃-4-基)乙酰胺 次甲霉素 A 桉叶油醇